2022
Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning.
Paulson N, Zeevi T, Papademetris M, Leapman MS, Onofrey JA, Sprenkle PC, Humphrey PA, Staib LH, Levi AW. Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning. JCO Clinical Cancer Informatics 2022, 6: e2200016. PMID: 36179281, DOI: 10.1200/cci.22.00016.Peer-Reviewed Original ResearchConceptsGrade group 2Prostate biopsyRadical prostatectomyAdverse outcomesGroup 2GG-2Core prostate biopsyProstate cancer outcomesPatient's clinical riskClinical risk assessmentCore needle biopsyOngoing clinical needAdverse outcome predictionRetrospective reviewAdverse pathologyCAPRA scoreEntire cohortCancer outcomesPathologic diagnosisNeedle biopsyClinical riskDisease outcomeProstate cancerBiopsyDisease one
2017
Prostate zonal anatomy correlates with the detection of prostate cancer on multiparametric magnetic resonance imaging/ultrasound fusion–targeted biopsy in patients with a solitary PI-RADS v2–scored lesion
Syed JS, Nguyen KA, Nawaf CB, Bhagat AM, Huber S, Levi A, Humphrey P, Weinreb JC, Schulam PG, Sprenkle PC. Prostate zonal anatomy correlates with the detection of prostate cancer on multiparametric magnetic resonance imaging/ultrasound fusion–targeted biopsy in patients with a solitary PI-RADS v2–scored lesion. Urologic Oncology Seminars And Original Investigations 2017, 35: 542.e19-542.e24. PMID: 28501565, DOI: 10.1016/j.urolonc.2017.04.011.Peer-Reviewed Original ResearchConceptsPositive predictive valueProstate cancerGleason scoreSuspicious findingsMultiparametric magnetic resonance imagingProstate multiparametric magnetic resonance imagingPeripheral zoneHigh positive predictive valueFusion-targeted biopsyProstate Imaging ReportingPI-RADS v2Category 4 lesionsMagnetic resonance imagingProstate zonal anatomySystematic biopsyProstate biopsyFusion biopsySingle lesionPatientsBiopsyPredictive valueImaging ReportingResonance imagingLesionsCancer